This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Uncategorised Disease
  • /
  • Tapentadol extended release in the management of p...
Journal

Tapentadol extended release in the management of peripheral diabetic neuropathic pain.

Read time: 1 mins
Published:25th Mar 2020
Author: Vadivelu N, Kai A, Maslin B, Kodumudi G, Legler A, Berger JM.
Ref.:Ther Clin Risk Manag. 2015 Jan 14;11:95-105.
DOI:10.2147/TCRM.S32193.

Tapentadol, a μ-opioid agonist and norepinephrine reuptake inhibitor, has been found to be an effective medication for a wide variety of chronic pain conditions, including back pain, cancer-related pain, and arthritic pain. It has also been found to have fewer gastrointestinal side effects than more traditional opioid-based therapies. More recently, tapentadol extended release has been demonstrated to be effective in the management of painful diabetic neuropathy, an often debilitating condition affecting approximately one-third of all patients with diabetes. This review highlights the most up-to-date basic and clinical studies by focusing on the mechanisms of action of tapentadol and its clinical efficacy, especially with regard to painful diabetic neuropathy.

Read abstract on library site